Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial-Reference-Cited by-同舟云学术

Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial

Published:2024-01-10 Issue:2 Volume:42 Page:140-145
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Zwanenburg Emma Sophia¹²^ORCID,El Klaver Charlotte¹²,Wisselink Daniel D.¹²,Punt Cornelis J.A.³,Snaebjornsson P.⁴⁵^ORCID,Crezee Johannes²⁶^ORCID,Aalbers Arend G.J.⁷,Brandt-Kerkhof Alexandra R.M.⁸,Bremers Andre J.A.⁹^ORCID,Burger Pim J.W.A.¹⁰,Fabry Hans F.J.¹¹,Ferenschild Floris T.J.¹²,Festen Sebastiaan¹³,van Grevenstein Wilhemina M.U.¹⁴,Hemmer Patrick H.J.¹⁵^ORCID,de Hingh Ignace H.J.T.⁹,Kok Niels F.M.⁷,Kusters M.¹²^ORCID,Musters G.D.¹²,Schoonderwoerd Lotte¹⁶,Tuynman J.B.²¹⁷^ORCID,van de Ven Anthony W.H.¹⁸,van Westreenen Henderik L.¹⁹,Wiezer M.J.²⁰,Zimmerman David D.E.²¹^ORCID,van Zweeden Annette²²,Dijkgraaf Marcel G.W.²³²⁴^ORCID,Tanis Pieter J.¹²⁸^ORCID,Andeweg Caroline S.,Bastiaenen Vivian P.,Bemelman Willem A.,van der Bilt Jarmila D.W.,Bloemen Johanne,den Boer Frank C.,Boerma Djamila,Huinink Daan ten Bokkel,Brokelman Walter J.A.,Cense Huib A.,Consten Esther C.J.,Creemers Geert-Jan,Crolla Rogier,Dekker Jan-Willem T.,Demelinne Jennifer,van Det Marc J.,van Diepen Karin K.,Diepeveen Marjolein,van Duyn Eino B.,van den Ende Esther D.,Evers Pauline,van Geloven Anna A.W.,van der Harst Erwin,Heemskerk Jeroen,Heikens Joost T.,Hess Daniel A.,Inberg Bas,Jansen Jan,Kloppenberg Frank W.H.,Kootstra Thomas J.M.,Kortekaas R.T.J.,Los Maartje,Madsen Eva V.E.,van der Mijle H.C.J.,Mol Linda,Neijenhuis Peter A.,Nienhuijs Simon W.,van den Nieuwenhof Loes,Peeters Koen C.M.J.,Polle Sebastiaan W.,Pon Jolien,Poortman Pieter,Radema Sandra A.,van Ramshorst Bert,de Reuver Philip R.,Rovers Koen P.,Schmitz Roderick F.,Sluiter Nina,Sommeijer Dirkje W.,Sonneveld Eric,van Sprundel T.C.,Veltkamp Sanne C.,Vermaas Maarten,Verwaal Victor J.,Wassenaar Emma,Wegdam Johannes A.,de Wilt Johannes H.W.,Westerterp Marinke,Wit Fennie,Witkamp Arjen J.,van Woensdregt Karlijn,van der Zaag Edwin S.,Zournas Mandy,

Affiliation:

1. Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands

2. Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands

3. UMC Utrecht, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands

4. Netherlands Cancer Institute, Department of Pathology, Amsterdam, the Netherlands

5. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

6. Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands

7. Netherlands Cancer Institute, Department of Surgery, Amsterdam, the Netherlands

8. Erasmus Medical Center, Department of Oncological and Gastrointestinal Surgery, Rotterdam, the Netherlands

9. Radboud University Medical Center, Department of Surgery, Nijmegen, the Netherlands

10. Catharina Hospital, Department of Surgery, Eindhoven, the Netherlands

11. Bravis Hospital, Department of Surgery, Roosendaal, the Netherlands

12. Maashospital Pantein, Department of Surgery, Beugen, the Netherlands

13. Department of Surgery, Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands

14. University Medical Center Utrecht, Department of Surgery, Utrecht, the Netherlands

15. University Medical Center Groningen, Department of Surgery, Groningen, the Netherlands

16. Bernhoven Hospital, Department of Surgery, Uden, the Netherlands

17. Amsterdam UMC Location Free University, Department of Surgery, Amsterdam, the Netherlands

18. Flevo Hospital, Department of Surgery, Almere, the Netherlands

19. Isala Hospital, Department of Surgery, Zwolle, the Netherlands

20. St Antonius Hospital, Department of Surgery, Nieuwegein, the Netherlands

21. Elisabeth-Tweesteden Hospital, Department of Surgery, Tilburg, the Netherlands

22. Amstelland Hospital, Department of Internal Medicine, Amstelveen, the Netherlands

23. Amsterdam UMC Location University of Amsterdam, Department of Epidemiology and Data Science, Amsterdam, the Netherlands

24. Amsterdam Public Health, Methodology, Amsterdam, the Netherlands

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Whether adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) might prevent peritoneal metastases after curative surgery for high-risk colon cancer is an ongoing debate. This study aimed to determine 5-year oncologic outcomes of the randomized multicenter COLOPEC trial, which included patients with clinical or pathologic T4N0-2M0 or perforated colon cancer and randomly assigned (1:1) to either adjuvant systemic chemotherapy and HIPEC (n = 100) or adjuvant systemic chemotherapy alone (n = 102). HIPEC was performed using a one-time administration of oxaliplatin (460 mg/m2, 30 minutes, 42°C, concurrent fluorouracil/leucovorin intravenously), either simultaneously (9%) or within 5-8 weeks (91%) after primary tumor resection. Outcomes were analyzed according to the intention-to-treat principle. Long-term data were available of all 202 patients included in the COLOPEC trial, with a median follow-up of 59 months (IQR, 54.5-64.5). No significant difference was found in 5-year overall survival rate between patients assigned to adjuvant HIPEC followed by systemic chemotherapy or only adjuvant systemic chemotherapy (69.6% v 70.9%, log-rank; P = .692). Five-year peritoneal metastases rates were 63.9% and 63.2% ( P = .907) and 5-year disease-free survival was 55.7% and 52.3% (log-rank; P = .875), respectively. No differences in quality-of-life outcomes were found. Our findings implicate that adjuvant HIPEC should still be performed in trial setting only.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02644

Reference17 articles.

1. Peritoneal Carcinomatosis in T4 Colorectal Cancer: Occurrence and Risk Factors

2. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer

3. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: Results of a population-based study

4. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

5. Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review